Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Sponsor
The First Affiliated Hospital of Xiamen University
Study ID
NCT05970666
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma

Key Dates

First listed
Aug 1, 2023
Start date
Nov 15, 2023
Status verified
Feb 2024
Primary completion
Nov 15, 2026
Completion
Nov 15, 2026

Study Design

Enrollment
71 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single arm

Primary Outcome Measure

Objective response rate（ORR） [ Time Frame: Up to 2 years ]

Central Contacts

Related Studies